QNEXA (phentermine plus topiramate) weight loss drug recommended for approval by FDA advisory panel

woman with anchor A novel weight loss drug might become available. Qnexa (a combination of the existing drugs phentermine and controlled release topiramate) was presented to the FDA in July 2010 and was rejected.

Now the manufacturer of the drug (Vivus) brought new information to the FDA Endocrinologic and Metabolic Advisory Committee today and the committee voted 20 to 2 that the medicine should be approved. It’s important to know that the FDA usually, but is not required to follow the guidance of its expert panels. The FDA briefing documents and advisory committee agenda are available at www.fda.gov.

young thin womanAn FDA press release will no doubt be forthcoming in the very near future. If it is approved, it could be the first addition to the weight loss category since 1999 and will be profiled in the Essential Guide to Prescription Drugs.

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.